YS Biopharma Financial Statements From 2010 to 2024

YS Stock   0.91  0.01  1.09%   
YS Biopharma financial statements provide useful quarterly and yearly information to potential YS Biopharma Co investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on YS Biopharma financial statements helps investors assess YS Biopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting YS Biopharma's valuation are summarized below:
Profit Margin
(0.67)
Market Capitalization
175.1 M
Enterprise Value Revenue
0.3608
Revenue
544.1 M
Earnings Share
(0.56)
There are over one hundred nineteen available fundamental measures for YS Biopharma, which can be analyzed over time and compared to other ratios. All traders should confirm YS Biopharma's latest fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 1.1 B in 2024. Enterprise Value is likely to drop to about 1.3 B in 2024

YS Biopharma Total Revenue

530.63 Million

Check YS Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among YS Biopharma main balance sheet or income statement drivers, such as Tax Provision of 969.1 K, Depreciation And Amortization of 35.1 M or Interest Expense of 23.2 M, as well as many exotic indicators such as Price To Sales Ratio of 1.63, Dividend Yield of 0.0 or PTB Ratio of 1.33. YS Biopharma financial statements analysis is a perfect complement when working with YS Biopharma Valuation or Volatility modules.
  
This module can also supplement various YS Biopharma Technical models . Check out the analysis of YS Biopharma Correlation against competitors.

YS Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.6 BB1.3 B
Slightly volatile
Short and Long Term Debt Total329.1 M573.4 M132.3 M
Slightly volatile
Other Current Liabilities376.6 M434.2 M337.7 M
Slightly volatile
Total Current Liabilities542.6 M757.6 M415.4 M
Slightly volatile
Property Plant And Equipment Net513.8 M670.3 M341.3 M
Slightly volatile
Current Deferred Revenue2.5 M2.6 M2.2 M
Slightly volatile
Accounts Payable46.8 M92.5 M28.7 M
Slightly volatile
Cash275.1 M333.1 M369.6 M
Slightly volatile
Non Current Assets Total658.1 M786.3 M505.3 M
Slightly volatile
Non Currrent Assets Other36.8 M18.8 M72.1 M
Slightly volatile
Long Term Debt201.2 M337.9 M73.3 M
Slightly volatile
Cash And Short Term Investments275.1 M333.1 M369.6 M
Slightly volatile
Net Receivables373.9 M532.5 M293.8 M
Slightly volatile
Common Stock Shares Outstanding101.7 M107 M93.9 M
Slightly volatile
Liabilities And Stockholders Equity1.6 BB1.3 B
Slightly volatile
Non Current Liabilities Total284.3 M299.3 M1.1 B
Slightly volatile
Capital Lease Obligations11.6 M10 M15.9 M
Slightly volatile
Inventory158.9 M213.2 M108 M
Slightly volatile
Other Current Assets6.8 M12 M2.5 M
Slightly volatile
Total Liabilities1.3 B892.2 M1.6 B
Slightly volatile
Property Plant And Equipment Gross715.9 M910.4 M515.6 M
Slightly volatile
Total Current Assets929.1 M1.2 B799.1 M
Slightly volatile
Capital Stock10.4 K14.1 K8.8 K
Slightly volatile
Net Working Capital281.1 M339.5 M370.4 M
Slightly volatile
Short Term Debt116.7 M228.3 M46.7 M
Slightly volatile
Intangible Assets64.7 M70.3 M81 M
Slightly volatile
Common Stock10.4 K14.1 K8.8 K
Slightly volatile
Short and Long Term Debt168 M222.8 M128.4 M
Slightly volatile

YS Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Tax Provision969.1 KM13.3 M
Slightly volatile
Depreciation And Amortization35.1 M42.2 M30.1 M
Slightly volatile
Interest Expense23.2 M35.5 M27.9 M
Pretty Stable
Selling General Administrative87.4 M73.6 M125.2 M
Slightly volatile
Selling And Marketing Expenses178.5 M289.3 M109.9 M
Slightly volatile
Total Revenue530.6 M790.3 M355.9 M
Slightly volatile
Gross Profit409.6 M613.9 M274.3 M
Slightly volatile
Other Operating Expenses652.2 M920.6 M476.3 M
Slightly volatile
Research Development228.9 M366.5 M144.2 M
Slightly volatile
Cost Of Revenue121 M176.4 M81.6 M
Slightly volatile
Total Operating Expenses531.2 M744.2 M394.7 M
Slightly volatile
Reconciled Depreciation35.1 M42.2 M30.1 M
Slightly volatile
Income Tax Expense969.1 KM13.3 M
Slightly volatile

YS Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based CompensationM3.2 M57.4 M
Slightly volatile
Begin Period Cash Flow243.3 M311.7 M82.6 M
Slightly volatile
Other Cashflows From Financing Activities517.2 M417.6 M899.2 M
Slightly volatile
Depreciation35.1 M42.2 M30.1 M
Slightly volatile
Other Non Cash Items13.8 M16.6 M11.1 M
Slightly volatile
Capital Expenditures48.8 M51.3 M107.3 M
Very volatile
Total Cash From Financing Activities379 M285.7 M631.9 M
Slightly volatile
End Period Cash Flow275.2 M333.3 M369.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.631.7117.4436
Slightly volatile
Days Sales Outstanding301283329
Slightly volatile
Average Payables44.5 M50.1 M54.5 M
Slightly volatile
Stock Based Compensation To Revenue0.00560.00590.2211
Slightly volatile
EV To Sales1.831.9316.4371
Slightly volatile
Inventory Turnover0.60.740.7285
Pretty Stable
Days Of Inventory On Hand535507499
Very volatile
Payables Turnover3.432.193.4254
Slightly volatile
Sales General And Administrative To Revenue0.130.140.4364
Slightly volatile
Average Inventory140.8 M158.3 M172.4 M
Slightly volatile
Research And Ddevelopement To Revenue0.340.420.3789
Slightly volatile
Cash Per Share4.094.574.145
Pretty Stable
Capex To Operating Cash Flow0.340.360.4942
Pretty Stable
Days Payables Outstanding103172111
Slightly volatile
Income Quality1.531.441.3335
Slightly volatile
Intangibles To Total Assets0.06350.05220.0671
Slightly volatile
Current Ratio1.951.812.021
Slightly volatile
Receivables Turnover1.11.341.1299
Slightly volatile
Graham Number12.4514.9315.656
Slightly volatile
Average Receivables308.6 M347.2 M378.1 M
Slightly volatile
Revenue Per Share4.176.653.6222
Slightly volatile
Interest Debt Per Share2.775.121.5655
Slightly volatile
Debt To Assets0.150.260.0758
Slightly volatile
Operating Cycle836790828
Slightly volatile
Days Of Payables Outstanding103172111
Slightly volatile
Ebt Per Ebit1.21.191.3011
Slightly volatile
Quick Ratio1.581.451.7247
Slightly volatile
Dividend Paid And Capex Coverage Ratio1.632.882.2769
Pretty Stable
Net Income Per E B T1.161.00791.0985
Very volatile
Cash Ratio0.830.651.004
Slightly volatile
Cash Conversion Cycle694570711
Slightly volatile
Days Of Inventory Outstanding535507499
Very volatile
Days Of Sales Outstanding301283329
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio2.01.511.5482
Slightly volatile
Fixed Asset Turnover0.821.061.0069
Pretty Stable
Capital Expenditure Coverage Ratio1.632.882.2769
Pretty Stable
Debt Ratio0.150.260.0758
Slightly volatile
Price Sales Ratio1.631.7117.4436
Slightly volatile
Asset Turnover0.260.360.2527
Slightly volatile
Gross Profit Margin0.620.70.7541
Slightly volatile

YS Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.1 B1.2 B4.8 B
Slightly volatile
Enterprise Value1.3 B1.3 B4.6 B
Slightly volatile

YS Biopharma Fundamental Market Drivers

Cash And Short Term Investments370.1 M

YS Biopharma Upcoming Events

22nd of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About YS Biopharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include YS Biopharma income statement, its balance sheet, and the statement of cash flows. YS Biopharma investors use historical funamental indicators, such as YS Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although YS Biopharma investors may use each financial statement separately, they are all related. The changes in YS Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on YS Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on YS Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in YS Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.6 M2.5 M
Total Revenue790.3 M530.6 M
Cost Of Revenue176.4 M121 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.14  0.13 
Research And Ddevelopement To Revenue 0.42  0.34 
Capex To Revenue(0.07)(0.08)
Revenue Per Share 6.65  4.17 
Ebit Per Revenue(0.18)(0.19)

Pair Trading with YS Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if YS Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in YS Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with YS Biopharma Stock

  0.69VALN Valneva SE ADRPairCorr

Moving against YS Biopharma Stock

  0.83DNA Ginkgo Bioworks HoldingsPairCorr
  0.82AQB AquaBounty TechnologiesPairCorr
  0.74EFTR Effector TherapeuticsPairCorr
  0.7KOD Kodiak SciencesPairCorr
  0.69VRNA Verona Pharma PLCPairCorr
The ability to find closely correlated positions to YS Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace YS Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back YS Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling YS Biopharma Co to buy it.
The correlation of YS Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as YS Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if YS Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for YS Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether YS Biopharma is a strong investment it is important to analyze YS Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact YS Biopharma's future performance. For an informed investment choice regarding YS Biopharma Stock, refer to the following important reports:
Check out the analysis of YS Biopharma Correlation against competitors.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for YS Biopharma Stock analysis

When running YS Biopharma's price analysis, check to measure YS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy YS Biopharma is operating at the current time. Most of YS Biopharma's value examination focuses on studying past and present price action to predict the probability of YS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move YS Biopharma's price. Additionally, you may evaluate how the addition of YS Biopharma to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Transaction History
View history of all your transactions and understand their impact on performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Is YS Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of YS Biopharma. If investors know YS Biopharma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about YS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
9.461
Earnings Share
(0.56)
Revenue Per Share
4.67
Quarterly Revenue Growth
(0.09)
Return On Assets
(0.10)
The market value of YS Biopharma is measured differently than its book value, which is the value of YS Biopharma that is recorded on the company's balance sheet. Investors also form their own opinion of YS Biopharma's value that differs from its market value or its book value, called intrinsic value, which is YS Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because YS Biopharma's market value can be influenced by many factors that don't directly affect YS Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between YS Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if YS Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, YS Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.